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Abstract
Spatial regulation of the tumor suppressor PTEN is exerted through alternative plasma
membrane, cytoplasmic, and nuclear subcellular locations. The N-terminal region of PTEN
is important for the control of PTEN subcellular localization and function. It contains both an
active nuclear localization signal (NLS) and an overlapping PIP2-binding motif (PBM) in-
volved in plasma membrane targeting. We report a comprehensive mutational and function-
al analysis of the PTEN N-terminus, including a panel of tumor-related mutations at this
region. Nuclear/cytoplasmic partitioning in mammalian cells and PIP3 phosphatase assays
in reconstituted S. cerevisiae defined categories of PTEN N-terminal mutations with distinct
PIP3 phosphatase and nuclear accumulation properties. Noticeably, most tumor-related
mutations that lost PIP3 phosphatase activity also displayed impaired nuclear localization.
Cell proliferation and soft-agar colony formation analysis in mammalian cells of mutations
with distinctive nuclear accumulation and catalytic activity patterns suggested a contribution
of both properties to PTEN tumor suppressor activity. Our functional dissection of the PTEN
N-terminus provides the basis for a systematic analysis of tumor-related and experimentally
engineered PTENmutations.
Introduction
The PI3K/PTEN/AKT pathway is involved in the etiology and progression of a wide variety of
human tumors, on account of genetic and epigenetic alterations in the genes that govern the
pathway, resulting in aberrant expression levels or activity of its components. In the case of
PI3K and AKT, these include protein overexpression or hyperactivity, mainly due to gene am-
plification or gain-of-function mutations [1–3]. In the case of PTEN, about 30% of human tu-
mors display protein downregulation or loss-of-activity, mainly due to total or partial gene loss
or gene transcription, decreased mRNA or protein stability, and loss-of-function mutations
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[4–6]. Remarkably, the genes encoding p110α (PIK3CA, α catalytic subunit of PI3K), AKT1,
and PTEN, are all targets for germ-line hereditary mutations in patients with PHTS (PTEN
Hamartoma Tumor Syndrome) [7]. Thus, the PI3K/PTEN/AKT pathway has arisen as a major
axis for therapeutic intervention in both sporadic and hereditary cancer [8].
The major role of PTEN as a potent tumor suppressor relies on its function as a lipid phos-
phatase, dephosphorylating the 3’ position of phosphatidylinositol 3,4,5-trisphosphate (PIP3)
to generate phosphatidylinositol 4,5-bisphosphate (PIP2), which directly antagonizes the onco-
genic activity of PI3K [9,10]. The N-terminal portion of PTEN, together with the C-terminal
phosphorylatable PTEN region, is crucial to exert its PIP3 phosphatase activity in cells, being
involved in the dynamic regulation of the PTEN open/closed conformational status, which dic-
tates PTEN subcellular localization, stability, and function [11–17]. C-terminal cleavage of
PTEN by caspase-3 triggers PTEN nuclear accumulation in a manner dependent on Ran
GTPase and a PTEN N-terminal nuclear localization signal (NLS; residues 8–32) [18,19].
PTEN N-terminus also harbours a PIP2-binding motif (PBM; residues 6–15) that mediates
binding to membranes, as well as allosteric activation of the enzyme [20–23]. Interestingly, a
cytoplasmic localization signal has also been described within this region (residues 19–25)
[24]. Nuclear PTEN regulates genome stability, DNA repair, cell cycle, gene expression, and
apoptosis [6,25–27], and the loss of PTEN nuclear localization associates in several cancers
with tumour progression and poor clinical outcome [28,29]. However, most of PTEN nuclear
functions rely on protein-protein interactions rather than on catalysis. Remarkably, monoubi-
quitylation of Lys13 at the NLS motif is required for PTEN nuclear entry [30], as well as for
PTEN secretion via exosomes, a novel PTEN export pathway [31]. In addition, a novel PTEN
isoform (PTEN-Long, PTENα; PTEN-L) has been discovered that displays an extended N-ter-
minus. This longer PTEN form can be targeted to the mitochondria and can also be secreted
and transferred, as a functional enzyme, from donor to acceptor cells, which is relevant for
PTEN-mediated tumor suppression and potential PTEN-based antitumor therapies [32–34].
Here, we have performed a comprehensive functional analysis of the PTEN N-terminal re-
gion (residues 2 to 43) using both a humanized S. cerevisiae-based system and human cancer
cell lines. We have uncovered the functional properties of tumor-associated mutations target-
ing the PTEN N-terminus, and functionally dissected this important region. Our results illus-
trate the multifaceted role of the PTEN N-terminus in the regulation of PTEN
tumor suppression.
Materials and Methods
Cell culture, transfections and plasmids
Simian kidney COS-7 (ATCC CRL-1651) cells were grown in DMEM containing high glucose
supplemented with 5% heat-inactivated fetal bovine serum (FBS), 1 mM L-glutamine,
100 U/ml penicillin, and 0.1 mg/ml streptomycin. Human osteosarcoma U2OS-derived UTA6
Tet-Off cell line containing Tet-Off plasmid was provided by R. Farràs [35]. U2OS Tet-Off
stable cells were grown in the same medium as COS-7 cells, supplemented with 10% FBS,
200 μg/ml geneticin (Invitrogen) and 100 μg/ml hygromycin (Sigma). Cells were grown at
37°C, 5% CO2. COS-7 cells were transfected by the DEAE-dextran method and processed after
48 h. To generate stable cell lines overexpressing ectopic PTEN wild type and mutations, U2OS
Tet-Off cell line was transfected with pTRE2hyg plasmids using the calcium phosphate meth-
od, and pooled clones were selected in the presence of 100 μg/ml of hygromycin. The Saccharo-
myces cerevisiae strain YPH499 (MATa ade2-101 trp1-63 leu2-1 ura3-52 his3-Δ200 lys2-801)
was used for heterologous expression of mammalian proteins. YPH499 yeast cells were grown
in synthetic complete (SC) medium, containing 0.17% yeast nitrogen base without amino
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acids, 0.5% ammonium sulfate supplemented with appropriate amino acids and nucleic acid
bases, and added 2% glucose (SD), galactose (SG) or raffinose (SR), as required. Yeasts were
transformed by standard procedures, and drop growth assays were performed as described
[36]. pRK5 PTEN constructs have been previously described [18]. The PTEN N-terminal
amino acid substitution mutations were made by PCR oligonucleotide site-directed mutagene-
sis, and mutations were confirmed by DNA sequencing. pTRE2hyg PTEN plasmids were made
by subcloning into pTRE2hyg of PCR-obtained PTEN cDNAs from the corresponding pRK5
constructs. YCpLG myc-p110α-CAAX and pYES2 PTEN plasmids have been described [36].
Cloning of PTEN mutations into pYES2 was made from the corresponding pRK5 PTENmam-
malian expression vectors.
Immunofluorescence and microscopy techniques
To monitor PTEN subcellular location in mammalian cells, immunofluorescence was per-
formed as previously described, using mouse monoclonal anti-PTEN 425A and fluorescein-
conjugated anti-mouse antibody [18,37]. For standard microscopy, a Zeiss fluorescence micro-
scope (Thornwood, NY) was used. For confocal microscopy, a Leica confocal microscope
(TCS-SP2-AOBS, Mannheim, Germany) was used. For quantitation of PTEN subcellular dis-
tribution, at least 100 positive cells were scored for each experiment. Cells were rated as show-
ing nuclear staining (N), cytoplasmic staining (C), or staining within both the nucleus and the
cytoplasm (N/C), as illustrated in Fig 1A. Nuclei were identified by Hoescht 33258 (Molecular
Probes, Eugene, OR) staining. All pictures were taken under a 400 X magnification. Measure-
ment of green fluorescent protein (GFP)-Akt1 plasma membrane localization in yeast, as an in-
direct indicator of cellular PIP3 levels, was performed by fluorescence microscopy, as described
[36].150 cells were examined and scored for each condition or experiment for either cyto-
plasmic or membrane-associated localization, as illustrated in Fig 1C. Cells were examined
under an Eclipse TE2000Umicroscope (Nikon) and digital images were acquired with Orca
C4742-95-12ER charge-coupled device camera and HCImage software (Hamamatsu).
Immunoblot
Whole cell protein extracts from U2OS cells overexpressing ectopic PTEN and mutations were
prepared by cell lysis in ice-cold lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mMNaCl, 1% IGE-
PAL CO-630 (Nonidet P-40), 2 mM Na3VO4, 100 mMNaF, 1mM PMSF, 1 μg/ml of aproti-
nine, 20 mM Na4P2O7), followed by centrifugation at 15200 g for 10 min and collection of the
supernatant. Yeast cell extracts were obtained by standard procedures. Proteins (50–100 μg in
the case of mammalian cells; 20–50 μg in the case of yeast) were resolved in 10% SDS-PAGE
under reducing conditions and transferred to PVDF membranes. Immunoblot was performed
using anti-phospho-Ser473-Akt + anti-phospho-Thr308-Akt and anti-Akt antibodies (Cell
Signaling Technologies), anti-PTEN 425A mAb (Andrés-Pons et al., 2005) or rabbit polyclonal
anti-PTEN antibodies (Upstate), anti-GAPDH (Santa Cruz Technology) or anti-actin C4 (MP
Biomedicals, France) antibodies, followed by horseradish peroxidase (HRP)-conjugated anti-
rabbit or anti-mouse (Calbiochem) antibodies. For determination of phospho-Akt content,
bands were quantified using ImageQuantTL software (Amersham Biosciences).
Cell growth assays
Cell growth of U2OS cells was measured as described [38]. For soft-agar growth assays, U2OS
Tet-Off cells were plated at a density of 15000 cells per well (12-well plates) in 2 ml of medium
with 20% FBS and 0.7% cell culture-tested agar (Sigma), onto the solidified bottom layer of
1.4% agar. Colonies were stained after 3–4 weeks with 0.05% crystal violet. For cell proliferation
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Fig 1. Depiction of the experimental systems used in this study (A) Subcellular localization of PTEN in
COS-7 cells. Ectopically expressed PTEN wild type (wt) mainly localizes in the cytoplasm (C) of COS-7 cells
(60–70% of transfected cells; upper panels), and some cells show nuclear/cytoplasmic (N/C) localization
(30–40% of transfected cells; middle panels). Cells were transfected with plasmids containing the indicated
PTEN forms, and subjected to immunofluorescence using anti-PTEN antibodies (green) or Hoechst nuclear
staining (blue). By contrast, PTEN 1–375 accumulates in the nucleus of COS-7 cells (80% of transfected
cells; lower panels). This feature was used to test the influence of amino acid substitution mutations on PTEN
nuclear accumulation. (B) Schematic showing the basis of the PTEN PIP3 functional assay in the yeast
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assays, the 3-[4,5-Dimethylthiazol-2-yl]-2,5-dephenyltetrazolium bromide assay (MTT) was
used according to the manufacturer’s protocol (Roche Applied Science). Cells were plated at a
density of 2500 cells per well (96-well plates) with complete medium, and cell proliferation was
determined at 1–5 days. Yeast cell growth was monitored on solid media by serial dilution-
drop growth assays, as described [36].
Results
Functional analysis of tumor-associated N-terminal PTEN mutations
In this study, we have monitored PTEN subcellular distribution and PIP3 phosphatase activity
using in parallel mammalian and yeast cell systems (Fig 1). When overexpressed in COS-7
cells, wild type PTEN displays a cytosolic or a nuclear/cytosolic distribution; in contrast, the
PTEN 1–375 truncation, which mimics a PTEN product of caspase-3 cleavage, accumulates in
the nucleus in an N-terminus-NLS-dependent manner (Fig 1A) [18,19]. Heterologous galac-
tose-inducible expression of p110α-CAAX (constitutively active, prenylatable form of the
p110α catalytic subunit of PI3K) results in high toxicity in S. cerevisiae yeast cells as a result of
the depletion of essential PIP2 pools. Co-expression of wild type PTEN restores PIP2 levels
and suppresses PI3K toxicity. Conversion of PIP3 to PIP2 by PTEN can be monitored either by
the suppression of PI3K-dependent yeast growth inhibition (Fig 1B) or by the relocation of a
heterologous Akt reporter from the plasma membrane (Fig 1C). This allows for rapid and reli-
able assessment of PTEN activity in vivo [36,39,40].
The PTEN N-terminal region contains motifs important for PTEN subcellular localization
and function (Fig 2A). To analyze the contribution of this region to PTEN tumor suppressor
function in vivo, we performed a functional analysis of a panel of tumor-associated N-terminal
PTEN mutations (COSMIC database; http://cancer.sanger.ac.uk/cosmic) (Fig 2; Table 1;
Table 2). The nuclear/cytosolic localization of the mutations was tested in mammalian COS-7
cells. On a PTEN wild type background (1–403), which mostly displays cytoplasmic localiza-
tion, the mutations L23F, M35R, and G36R showed increased nuclear localization (Fig 2B;
Table 1). In contrast, on a PTEN 1–375 background, a different pattern of PTEN nuclear/cyto-
solic partition in such mutations was observed (Fig 2B and 2C; Table 2). The mutations K13E,
A34D, and L42P, fully abrogated the nuclear accumulation of PTEN 1–375. A partial inhibition
of nuclear accumulation was observed with the R15I, R15S, D24Y, I33S, M35R, and G36R mu-
tations, whereas the nuclear/cytoplasmic distribution of S10N, Y16C, L23F, and A34V muta-
tions was not significantly altered. It is likely that changes in both nuclear active shuttling and
binding to plasma membrane account for the different subcellular distribution patterns of
these PTEN mutations.
Next, the PIP3 phosphatase activity of the tumor-associated N-terminal PTEN mutations
was assessed using the S. cerevisiae heterologous reconstitution system. In these experiments,
the mutations were tested in a PTEN 1–403 background, and the expression levels of all mu-
tants were similar to the expression levels of wild type PTEN (Fig 2E) suggesting that the tested
tumor-associated N-terminal PTEN mutations do not affect PTEN protein stability. As shown
in Fig 2D and 2E, and Table 2, the mutations K13E, R15I, R15S, D24Y, I33S, A34D, M35R,
S. cerevisiae. Yeast cells expressing p110α-CAAX (a constitutive active form of the p110α catalytic subunit of
mammalian PI3K under the control ofGAL1 promoter) do not grow, and this can be reverted by expressing
PTEN wild type. This feature was used to indirectly measure PTEN phosphatase activity, by reconstituting
yeast viability. (C) Indirect measurement of PIP3 hydrolysis by PTEN in yeast is visualized by GFP-Akt1
reporter distribution. In the presence of p110α-CAAX alone (left panel), the GFP-Akt1 reported distributes in
the plasmamembrane as a result of PIP3 acccumulation [PIP3(+)], whereas in the presence of p110α-CAAX +
PTEN wt, GFP-Akt1 displays a diffuse cytoplasmic distribution as a result of PIP3 hydrolysis [PIP3(-)].
doi:10.1371/journal.pone.0119287.g001
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Fig 2. Subcellular localization and functional analysis of tumor-associated N-terminal PTENmutations. (A) Amino acid sequence of PTEN N-
terminus (residues 1–43). The nuclear localization signal (NLS), the PIP2-binding motif (PBM), and the cytoplasmic localization signal (CLS) are indicated.
The KRRmotif (residues 13–15) is in red. (B, C) The influence of tumor-associated PTENmutations on PTEN subcellular localization was assessed by
Functional Analysis of PTEN N-Terminus
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G36R, and L42P totally abrogated PTEN activity in the yeast model, whereas mutations S10N,
Y16C, L23F, and A34V partially reduced PTEN activity. Interestingly, the latter tumor-associ-
ated mutations that did not strongly affect PTEN activity, did not significantly modify the
PTEN 1–375 nuclear/cytosolic distribution either, pointing towards an overlapping tumor sup-
pressor role of the PTEN N-terminus for its PIP3 catalytic activity and its nuclear localization
in vivo (Table 2).
Functional analysis of PTEN N-terminal region by comprehensive
mutagenesis
To further dissect the involvement of PTEN N-terminal region in its function, we performed a
full Ala-scanning mutagenesis of the PTEN region from residue 2 to residue 43 (Ala residues
were mutated to Val). The mutated region spans the N-terminal PTEN tail and the three N-ter-
minal β-strands at the PTP domain (Fig 2A and Fig 3C). Both subcellular localization and
yeast reconstitution experiments were performed. Mutations at the basic residues of the N-
immunofluoresecence on mammalian COS-7 cells. In B, COS-7 cells transfected with wild type (wt; 1–403) or mutated PTEN (1–375, or mutations in a 1–375
background) were analysed by standard immunofluorescence microscopy using anti-PTEN 425AmAb (green). Nuclei were stained with Hoechst (blue). In
C, the nuclear/cytoplasmic distribution of PTENmutations was scored from COS-7 cells processed as in B; N, nuclear localization; C, cytoplasmic
localization; N/C, nuclear/cytoplasmic localization. (D, E). The influence of tumor-associated PTENmutations in the in vivo PTEN PIP3 phosphatase activity
was assessed in yeast. In D, S. cerevisiae drop growth experiments were performed on co-transformants expressing p110α-CAAX and the indicated PTEN
mutations, under repression (Glucose) or induction (Galactose) of the expression of the heterologous mammalian proteins. Expression of p110α-CAAX
results in high toxicity in yeast cells as a result of the depletion of essential PIP2, which is converted to PIP3. Co-expression of wild type PTEN hydrolyses
PIP3 and restores PIP2 levels and viability. In E, PIP3 hydrolysis by PTEN in yeast cells was monitored indirectly using a GFP-Akt1 reporter protein. Results
are shown as percentage of yeast cells that display GFP-Akt1 at the plasmamembrane (PM). The bottom panel shows the equivalent expression in the yeast
of all PTENmutations, as assessed by immunoblot using anti-PTEN and anti-actin (as a loading control) antibodies.
doi:10.1371/journal.pone.0119287.g002
Table 1. Subcellular localization of tumor-associated PTENmutationsmotif on a PTEN 1–403
background.
Subcellular localization (%)*
Mutation N C N/C
wt 0 67 33
S10N 0 72 28
K13E 0 70 30
R15I 0 68 32
R15S 0 92 8
Y16C 2 94 4
L23F 8 25 67
D24Y 0 61 39
I33S 3 70 27
A34D 0 83 17
A34V 0 74 26
M35R 34 2 64
G36R 47 7 46
L42P 0 88 12
*Percentage of COS-7 cells showing nuclear (N), cytoplasmic (C), or nuclear/cytoplasmic staining (N/C) is
indicated. Note that, in the context of PTEN wild type (wt) 1–403, most of the mutations displayed
predominant cytoplasmic localization. The mutations L23F, M35R, and G36R favored PTEN 1–403 nuclear
accumulation. Mutations are from COSMIC database (http://cancer.sanger.ac.uk/cosmic)
doi:10.1371/journal.pone.0119287.t001
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terminus NLS region, including K13A, R14A, and R15A, as well as mutations E7A, Y16A,
D24A, Y27A, I28A, P30A, N31A, I32A, I33A, and L42A, inhibited nuclear entry of PTEN
1–375, whereas mutations N12A, E18A, M35A, and A39V also inhibited nuclear accumulation
but to a lesser extent (Fig 3A; and [18]). On the other hand, the cytoplasmic localization of
PTEN 1–403 shifted partially to the nucleus in the mutations D19A, G20A, and F21A
(Table 3), in consistence with a previously mapped cytoplasmic localization signal (CLS) at
these residues [24]. Thus, several regions at the PTEN N-terminus are important for PTEN
nuclear localization.
Regarding the PIP3 phosphatase activity of the PTEN mutations in the yeast in vivo assay, a
set of mutations, including R15A, Y16A, D24A, I32A, M35A, P38A, and A39V, displayed com-
plete loss-of-function, whereas the rest of the mutations partially compromised (A3V, I4A,
I5A, K6A, S10A, Q17A, I33A, and L42A) or did not considerably affect PTEN activity on PIP3
in yeast (Fig 3B). The expression of all mutant versions was similar to the expression of wild
type PTEN (Fig 3B). Therefore, many of the mutations differentially affected PTEN nuclear ac-
cumulation and PTEN phosphatase activity in vivo, suggesting a distinctive control of these
two processes. Also, mutations R15A, Y16A, D24A, I32A, I33A, M35A, A39V, and L42A abro-
gated both nuclear accumulation and PIP3 phosphatase activity of PTEN, indicating that the
relationship between these two properties extends beyond the NLS- and the PBM-residues (Fig
3C). Together, these results provide a map of the contribution of particular residues at distinct
PTEN N-terminal regions to both subcellular localization and catalytic activity in vivo. PTEN
N-terminal mutations can thus be categorized in three sub-groups: a group affecting PIP3
Table 2. PIP3 functional analysis and subcellular localization of tumor-associated PTENmutations.
Mutation PIP3 in vivo activity* Subcellular localization† Tumor type/disease#
wt 1–403 + C
wt 1–375 + N
S10N +/- N LC,NHML,EC
K13E - C CS,Glb,EC
R15I - N/C Glb,EC
R15S - N/C CS,ASD,Glb,CC
Y16C +/- N Glb,NHML
L23F +/- N Glb
D24Y - N/C or C BRR,CS,EC,OC,BD
I33S - N/C Glb,EC
A34D - C BRR,EC
A34V +/- N EC
M35R - N/C JPS,Glb
G36R - N/C CS,LDD,Glb,SS
L42P - C Glb
* PIP3 in vivo activity in yeast was monitored by the reconstitution of the p110α-CAAX-induced lack-of-growth phenotype (+, reconstitution; +/-, partial
reconstitution;-, no reconstitution). Data of mutations are on a PTEN 1–403 background, from Fig 2 and from [36].
† Major subcellular localization (N, nucleus; C, cytoplasm; N/C, nucleus/cytoplasm) was determined by immunofluorescence on mammalian COS-7 cells.
Data of mutations are on a PTEN 1–375 background, from Fig 2.
# From COSMIC (http://cancer.sanger.ac.uk/cosmic) and HGMD (http://www.hgmd.cf.ac.uk) databases. Abbreviations: BD, bladder cancer; BRR,
Bannayan-Riley-Ruvalcaba syndrome; CC, colon carcinoma; CS, Cowden syndrome; EC, endometrial cancer; Glb, glioblastoma; JPS, juvenile polyposis
syndrome; LC, lung carcinoma; LDD, Lhermitte-Duclos disease; NHML, non-Hodgkin’s malignant lymphoma; OC, ovarian carcinoma; SC, stomach
carcinoma; SS, synovial sarcoma. In italic, germ-line mutations.
doi:10.1371/journal.pone.0119287.t002
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Fig 3. Subcellular localization and functional analysis by Ala-scanning of PTEN N-terminal region reveals distinct subgroups of PTENmutations.
(A) Nuclear/cytoplasmic distribution of PTEN N-terminal mutations, monitored as in Fig 2C. Nuclear/cytoplasmic distribution of mutations V9A to E18A is as
in [18]. (B) Influence of PTEN N-terminal mutations in the in vivo PTEN PIP3 phosphatase activity, assessed in yeast. In the upper panel (bars graph), the
PIP3 phosphatase activity of PTEN N-terminal mutations was monitored as in Fig 2E. In the middle panel (drop growth), growth was monitored as in Fig 2D.
The activity of mutations K6A to E18A is as in [36]. In the bottom panel, the equivalent expression in the yeast of all PTENmutations, as assessed by
immunoblot using anti-PTEN antibodies, is shown. (C) Scheme summarizing the Ala-scanning functional results and the distinct subgroups of PTEN
mutations. PTEN N-terminal amino acid sequence (residues 1–43) is shown, and the NLS (grey) motif is indicated. The functional consequences of each Ala-
substitution are indicated with a colour code: green (+ +), no effect; yellow (- +), normal PIP3 phosphatase activity but impaired nuclear accumulation; blue
(+-), impaired phosphatase activity but normal nuclear accumulation; red (—), impaired phosphatase activity and nuclear accumulation. For nuclear
Functional Analysis of PTEN N-Terminus
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phosphatase activity, a group involved in nuclear accumulation, and a third group involved in
both phosphatase activity and nuclear localization.
Differential involvement of residues at the PTEN N-terminal KRRmotif in
PTEN phosphatase activity and subcellular localization
Since specific residues from the positively charged motif at the PTEN N-terminus NLS
(Lys13Arg14Arg15; KRR motif) (Fig 2A) are important for nuclear localization or phosphatase
activity in vivo, we performed additional amino acid substitutions in this motif aimed to
change its charge and/or its bulk. As shown in Fig 4A, charge conservative replacement K13R
and R14K mutations, as well as K13E mutation, affected the nuclear localization of PTEN
1–375. It should be mentioned that inhibition of nuclear accumulation on PTEN 1-375/K13R
associated with increased plasma membrane localization, as evidenced by confocal microscopy
(Fig 4B). On the other hand, mutation R15K did not inhibit PTEN 1–375 nuclear accumula-
tion, and increased the nuclear accumulation of PTEN 1–403 (Fig 4A, Table 4). Thus, Lys13
and Arg14, but not Arg15, are essential for PTEN nuclear accumulation. Combined mutations
rendering either a KKK (R14K/R15K) or an AAA (K13A/R14A/R15A) motif were also exclud-
ed from the nucleus, whereas the mutation rendering a RAA (K13R/R14A/R15A) motif dis-
played a partial nuclear accumulation. In contrast to the results obtained for PTEN nuclear
accumulation, the R15K mutation did not display phosphatase activity in vivo, whereas the ac-
tivity of the K13R and R14K mutations was not diminished in comparison with wild type
PTEN. In fact, the K13R mutation even displayed an increased ability to counteract PI3K activ-
ity in the yeast model. Finally, the activity of mutation K13E was totally absent (Fig 4C). The
expression of all mutations at the KRR motif was similar to the expression of wild type PTEN
(Fig 4C). These results confirm that Arg15, but not Lys13 or Arg14, is essential for the PIP3
phosphatase activity of PTEN in vivo. This is in agreement with the finding that Arg15 is criti-
cal for targeting PTEN to the plasma membrane [41]. Together, our results reveal a differential
and complementary involvement of PTEN residues Lys13, Arg14, and Arg15 in PTEN nuclear
localization and phosphatase activity in cells.
Functional analysis of PTEN N-terminal mutations in mammalian cells
To test the function on mammalian cells of PTEN N-terminal mutations displaying distinctive
nuclear accumulation, stable human osteosarcoma U2OS Tet-Off cell lines expressing PTEN
1-375/L23F and 1-375/N31A mutations were generated, and cell proliferation and soft-agar
focus formation assays were performed. As a comparison, cells expressing empty vector, PTEN
wild type, or PTEN 1–375 were also analysed (Fig 5A). As shown above, the L23F mutation dis-
plays compromised/partial PIP3 catalytic activity in the yeast, without affecting the nuclear ac-
cumulation of PTEN 1–375 in mammalian cells. Conversely, the N31A mutation did not affect
PIP3 catalytic activity in the yeast, but impaired the nuclear accumulation of PTEN 1–375 in
mammalian cells (Fig 2 and Fig 3). Cells expressing PTEN 1–375 grew slower on plastic and
formed less colonies in soft agar than cells expressing PTEN wild type. Remarkably, cells ex-
pressing PTEN 1-375/L23F behaved in both assays as empty vector cells, indicating a complete
loss-of-function of this mutation in mammalian cells in terms of cell growth inhibitory capaci-
ty. On the other hand, cells expressing PTEN 1-375/N31A behaved as PTEN wild type cells,
localization in the background of PTEN 1–375, we consider positive those mutants that showed over 50% of cells with nuclear localization. For in vivo activity
on PIP3, we consider positive those mutants that showed under 30% of cells with Akt at the plasmamembrane and significantly rescued p110α-induced
growth inhibition. The first Met (M) was not mutated, and corresponds to PTEN wild type.
doi:10.1371/journal.pone.0119287.g003
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Table 3. Subcellular localization of Ala-scanning PTENmutations on a PTEN 1–403 background.
Subcellular localization (%)*
Mutation N C N/C
T2A 0 65 35
A3V 0 60 40
I4A 9 71 21
I5A 0 71 30
K6A 0 68 32
E7A 1 82 18
I8A 0 72 28
V9A 0 65 35
S10A 0 69 31
R11A 0 54 46
N12A 0 71 29
K13A 0 90 10
R14A 0 81 19
R15A 0 74 26
Y16A 0 77 23
Q17A 0 80 20
E18A 0 75 25
D19A 17 12 71
G20A 47 3 50
F21A 61 2 37
D22A 9 66 25
L23A 0 61 39
D24A 6 75 19
L25A 2 64 34
T26A 0 77 23
Y27A 0 57 44
I28A 0 65 35
Y29A 0 64 36
P30A 0 68 33
N31A 0 50 50
I32A 0 63 37
I33A 3 70 27
A34V 0 74 26
M35A 0 70 30
G36A 0 64 36
F37A 0 69 31
P38A 1 70 29
A39V 0 55 45
E40A 0 65 35
R41A 0 70 30
L42A 0 78 22
E43A 0 71 29
*Percentage of COS-7 cells showing nuclear (N), cytoplasmic (C), or nuclear/cytoplasmic staining (N/C) is
indicated. Note that, in the context of PTEN 1–403, most of the mutations did not affect the localization of
PTEN wild type (wt), with the exception of some mutations in the cytoplasmic localization signal at residues
19–25, which favored PTEN 1–403 nuclear accumulation
doi:10.1371/journal.pone.0119287.t003
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displaying better growing properties than PTEN 1/375 cells (Fig 5B and 5C). These results sup-
port the notion that partial loss of PIP3 phosphatase activity of PTEN is enough to confer a
loss-of-function phenotype in mammalian cells, and suggest that impairment of PTEN nuclear
accumulation may affect the full capacity of PTEN to control cell growth.
Fig 4. Subcellular localization and functional analysis of PTENmutations at the N-terminal KRRmotif. (A) Arg13 and Lys14 are essential for nuclear
localization. The nuclear/cytoplasmic distribution of PTENmutations at the KRRmotif was monitored by standard immunofluorescence microscopy, as in
Fig 2C. *Note that standard microscopy does not provide information on plasmamembrane localization for K13R (see B, panel f). KKK, R14K/R15K;
AAA, K13A/R14A/R15A; RAA, K13R/R14A/R15A. (B) COS-7 cells transfected with PTEN wild type (wt) or mutations were analysed by confocal
immunofluorescence microscopy using anti-PTEN 425AmAb (green). Nuclei were stained with Hoechst (blue). Note the plasmamembrane staining on the
PTEN 1–375 K13Rmutation (panel f). (C) Arg15 is essential for PIP3 phosphatase activity. The influence of PTENmutations at the KRRmotif in the in vivo
PTEN PIP3 phosphatase activity was assessed in yeast. In the upper panel (bars graph), the PIP3 phosphatase activity of PTENmutations at the KRRmotif
was monitored as in Fig 2E. The middle panel shows the equivalent expression in the yeast of all PTENmutations, as assessed by immunoblot using anti-
PTEN antibodies. In the bottom panel (drop growth), growth was monitored as in Fig 2D.
doi:10.1371/journal.pone.0119287.g004
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Discussion
PTEN is the second most frequently mutated tumor suppressor gene in human cancers. Al-
though tumor-associated gross mutations in PTEN abrogate all its tumor suppressor functions
by means of complete loss of the PTEN protein, the phenotype caused by disease-linked PTEN
point mutations is more variable. This could be relevant for the implementation of specific
therapies and preventive measures to patients and affected families. For instance, most of the
germ-line PTEN point mutations found in patients with PHTS abrogate PTEN PIP3-phospha-
tase activity. By contrast, some patients with autism spectrum disorders are also carriers of
PTEN germ-line point mutations and such variants do not result, in general, in total loss of
PTEN PIP3 phosphatase activity [42–44]. In addition to PTEN intrinsic catalysis, other biolog-
ical properties of PTEN, including protein-protein interactions and subcellular localization,
may be determinant for its lipid phosphatase activity and tumor suppression in vivo. This
makes multifunctional analyses of the PTEN variants found in patients necessary.
The N-terminal region of PTEN contains overlapping NLS/PBM motifs that regulate PTEN
subcellular localization and catalytic activity, and this region is targeted by tumor-associated
mutations with high incidence (15% of PTEN total mutated samples target residues 1–40;
about 40% of these being missense mutations; COSMIC database). Moreover, some PTEN
tumor-associated mutations at PTEN N-terminus display a reduced ability to bind to the plas-
ma membrane [45]. Our functional analysis of the PTEN N-terminus illustrates that tumor-as-
sociated mutations in this PTEN region are selected for loss-of-function, in terms of PIP3
phosphatase activity in a yeast-based in vivo setting and nuclear localization in mammalian
cells, indicating the additive relevance of both properties in PTEN-mediated tumor suppres-
sion. This is in agreement with the distinct lipid phosphatase-independent tumor suppressor
functions ascribed to nuclear PTEN [46–51]. By contrast, tumor-associated mutations target-
ing other PTEN regions, including the ATP-binding sites, show enhanced nuclear accumula-
tion [52]. The lack of nuclear PTEN in many human cancers has been documented, and
proposed as a factor of poor prognosis for some tumor types [27]. It would be interesting to
contrast these findings on PTEN nuclear exclusion in human tumors with the analysis of the
phosphatase activity of the non-nuclear remnant PTEN protein. The KRR residues 13–15 in
the PTEN NLS/PBM, as well as the β2-sheet residues 31–36, are targeted in tumors for loss-of-
function mutations (Table 1). The KRR residues are likely to mediate direct interactions with
Table 4. Subcellular localization of PTENmutations at the N-terminal KRRmotif on a PTEN 1–403
background.
Subcellular localization (%)*
Mutation N C N/C
K13R 8 46 46
K13E 0 75 25
R14K 0 73 27
R15K 44 18 38
KKK 0 72 28
AAA 0 74 26
RAA 0 75 25
*Percentage of COS-7 cells showing nuclear (N), cytoplasmic (C), or nuclear/cytoplasmic staining (N/C) is
indicated. KKK, R14K/R15K; AAA, K13A/R14A/R15A; RAA, K13R/R14A/R15A. Note that the mutation
R15K favored PTEN 1–403 nuclear accumulation.
doi:10.1371/journal.pone.0119287.t004
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PIP2 or nuclear transporters, required for PTEN catalysis and nuclear accumulation
[18,20,23,53]. On the other hand, the PTEN residues at the β2-sheet are highly hydrophobic
and not solvent-exposed [54], suggesting that mutations at this region compromise functional
PTEN local folding. In this regard, our Ala-scanning functional analysis suggests that the integ-
rity of Lys13, Arg14, and residues 31–36, is more relevant for nuclear accumulation than for
Fig 5. Functional analysis in mammalian cells of PTENmutations displaying distinctive nuclear accumulation and PIP3 phosphatase activity. (A)
The ectopic expression of PTEN wild type (WT) and mutations in U2OS clones was monitored by immunoblot with an anti-PTEN antibody (upper panel). The
arrows indicate the migration of the full-length (residues 1–403) or the truncated (residues 1–375) recombinant PTEN. Expression of GAPDH is shown in the
lower panel as a loading control. The figure shows non-adjacent bands from the same blot. (B) Proliferation of the distinct U2OS clones during 5 days of
culture. Data are shown as the mean + SD of the absorbance from three experiments, corrected for background.-, empty vector. (D) Growth in soft agar of the
distinct U2OS clones. Cells were plated on soft agar, and pictures (X40 magnification) were made after 3–4 weeks of growth (upper part). The bottom graph
shows the quantification of the number of colonies per plate for each clone. Data are shown as the mean + SD from three independent experiments.
** p<0.001, * p<0.05 with respect to PTEN wild type.-, empty vector.
doi:10.1371/journal.pone.0119287.g005
Functional Analysis of PTEN N-Terminus
PLOS ONE | DOI:10.1371/journal.pone.0119287 April 15, 2015 14 / 18
PIP3 phosphatase activity in vivo. On the other hand, integrity of Lys15 and Tyr16 seems to be
more important for PIP3 phosphatase activity than for nuclear accumulation. We have found
several functional categories of PTEN mutations in our Ala-scanning analysis, including muta-
tions that did neither affect nuclear accumulation nor PIP3 phosphatase activity (+ +), muta-
tions that compromised both nuclear accumulation and PIP3 phosphatase activity (—), and
mutations that discriminated between these two functions (+-) (- +) (Fig 2C). In conclusion, al-
though PTEN-PIP2 binding and PTEN-nuclear transport mechanisms share recognition mo-
tifs, our results suggest the existence of specific molecular determinants for each of these two
activities on the PTEN N-terminus. In line with this notion, the K13R mutation favored PTEN
targeting to the plasma membrane in a nuclear-PTEN-mutation background (PTEN 1-375/
K13R), but not in the cytosolic wild type-PTEN background (PTEN K13R). A similar phenom-
ena has been found for other PTEN mutations, including mutations at the PTEN N-terminus,
which increased their accumulation at the plasma membrane when combined with a PTEN C-
terminal-phosphorylation defective mutation [41,42]. Interestingly, sandwiched between clus-
ters of residues important for nuclear localization at the PTEN N-terminus, a cytoplasmic lo-
calization signal has been described at residues 19–25 [24]. Our finding that PTEN mutations
in this region partially shift to the nucleus support the idea that it could behave similarly to the
nuclear exclusion motifs defined in other PTEN regions [18]. This documents the complexity
of PTEN N-terminus as a determinant to drive mechanisms of subcellular targeting.
We have tested in mammalian cells the tumor suppressor capacity of PTEN mutations dis-
playing differential PIP3 phosphatase activity and nuclear accumulation properties. The cas-
pase-3 mimicking PTEN C-terminal truncation, PTEN 1–375, which accumulates in the
nucleus, displayed enhanced cell growth inhibition, when compared to PTEN wild type. Since
the presence of an intact PTEN C-terminal tail keeps PTEN in a closed inactive conformation,
which is neither competent to go to the nucleus nor to the plasma membrane [11,13,14,17], it
is difficult to delimitate the contribution of the nuclear accumulation of PTEN 1–375 on its
tumor suppressor activity. Our results using PTEN 1-375/L23F and 1-375/N31A mutations in-
dicate that both the PTEN PIP3 phosphatase activity and the PTEN capacity to accumulate in
the nucleus are important for PTEN tumor suppression.
Also of interest is our finding that Ala-substitution of residues at the non-crystalized disor-
dered N-terminal PTEN region, including Ala3, Ile4, and Ile5, affects PTEN PIP3 phosphatase
activity in vivo, suggesting the existence of additional PTEN regulatory elements in this region.
This is sustained by the presence of PTENmutations targeting these PTEN N-terminal residues
in tumors (COSMIC database). Importantly, residues within the unique region of the PTEN
longer isoform, contiguous to the region studied here, are also targeted by mutations in tumors
[32], although the intrinsic PIP3 catalytic activity of these mutations is not altered when as-
sessed in the yeast [55]. Further molecular and in vivo analyses are necessary to fully under-
stand the regulatory mechanisms imposed by the standard PTEN N-terminus, and by the
adjacent residues from the PTEN longer isoform, to PTEN tumor suppressor function in mam-
malian cells. Our comprehensive functional analysis of PTEN N-terminus provides a founda-
tion to understand and exploit the N-terminal properties of PTEN to intervene therapeutically
in PTEN-mediated tumor suppression.
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